How should the safety and efficacy of platelet transfusions be assured?

Blood Reviews

Volumn 12, Issue 4, 1998, Pages 203-214

  Williamson, L M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; HLA ANTIBODY;

ALLOIMMUNIZATION; BACTERIUM CONTAMINATION; BLOOD TRANSFUSION REACTION; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION COMPLICATION; LUNG INJURY; PRIORITY JOURNAL; REVIEW; SAFETY; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; VIRUS TRANSMISSION;

EID: 0032414501     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90000-5     Document Type: Conference Paper

References (104)

1. Williams AE, Thomson RA, Schreiber GB et al. Estimates of infectious disease risk factors in US blood donors. JAMA 1997; 277: 967-972.
2. Soldan K, Barbara JAJB. Estimation of the risk of HIV, HCV and HBV infectious blood donations entering the blood supply in England (Unpublished data).
3. Schreiber GB, Busch MP, Kleinman SH et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-1690.
4. Vyas GN, Yang G, Murphy EL. Transfusion-related transmissible diseases: detection by polymerase chain reaction - amplified genes of the microbial agents. Trans Med Rev 1994, VIII, 253-266.
5. Corash L. Inactivation of viruses in human cellular blood components. Vox Sang 1994; 67: 211-216.
6. Wagner SJ, Bardossy L, Moroff G et al. Assessment of the hemostatic effectiveness of human platelets treated with aminomethyltrimethyl psoralen and UVA light using a rabbit ear bleeding time technique. Blood 1993; 82: 3489-3492.
7. Lin L et al. Photochemical inactivation of cell-assocated human immunodeficiency virus in platelet concentrates. Blood 1993; 82: 292-297.
8. Blajchman MA, Ali AM, Richardson HL. Bacterial contamination of cellular blood components. Vox Sang 1994; 67; 25-34.
9. Olsen KE, Sandler SG. Febrile neutropenia contributes to underreporting of potential septic platelet transfusion reactions. (Letter). Vox Sang 1996; 70: 118.
10. Chiu EKW, Yuen KY, Lie AKW et al. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 1994; 34: 950-954.
11. Dave J, Brett M, MacLennan S et al. Sepsis associated with blood transfusion. (Letter) Lancet 1996; 347: 1773.
12. Heltberg O, Skov F, Gerner-Smidt P et al. Nosocomial epidemic of Serratia marcescens septicemia ascribed to contaminated blood transfusion bags. Transfusion 1993; 33: 221-227.
13. Morrow JF, Braine JG, Kickler TS et al. Septic reactions to platelet transfusions. JAMA 1991; 266; 555-558.
14. Yomtovian R, Lazarus HM, Goodnough LT et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33: 902-909.
15. Initiation of a national study to detect bacteria-associated transfusion reactions. CDC Morbidity and Mortality Weekly Report 1997; 46: 554-555.
16. Thorpe TC, Wilson ML, Turner JS et al. BacT/Alert: an automated colorimetric microbial detection system. J Clin Microbiol 1990; 28: 1608-1612.
17. Brecher ME, Boothe G, Kerr A. The use of chemiluminescence-linked universal bacterial ribosomal RNA gene probe and blood gas analysis for the rapid detection of bacterial contamination in white cell-reduced and non-reduced platelets. Transfusion 1993; 33: 450-457.
18. Lin L, Cook DN, Wiesehahn GP et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37: 423-435.
19. Mendelson M, Monard S, Sissons P et al. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J Gen Virol 1996; 77: 3099-3102.
20. Smith KL, Cobain T, Dunstan RA. Removal of cytomegalovirus DNA from donor blood by nitration. Br J Haem 1993; 83: 640-642.
21. Murphy MF, Grint PCA, Hardiman AE et al. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. (Letter). Br J Haem 1988; 70: 253-255.
22. Gilbert GL, Hayes K, Hudson IL et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Lancet 1989; I: 1228-1231.
23. Graan-Hentzen YCE, Gratama JW, Mudde GC et al. Prevention of primary cytomegalovirus infections in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989; B29B: 757-760.
24. Bowden RA, Slichter SJ, Sayers MH et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78: 246-250.
25. Bowden RA, Slichter SJ, Sayers M et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-3603.
26. Council of Europe. Guide to the Use, Preparation and Quality Control of Blood Components, 3rd edn. Council of Europe Publishing, Strasbourg, 1997.
27. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet 1991; 337; 1435-1439.
28. Kataoka R, Takehara N, Iwahara Y et al. Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbits. Blood 1990; 76: 1657-1661.
29. AI EJM, Visser SCE, Broerson SM et al. Reduction of HTLV-I-infected cells in blood by leukocyte filtration. Ann Hematol 1993; 67: 295-300.
30. Buchholz DH, AuBuchon JP, Snyder EL et al. Effects of white cell reduction on the resistance of blood components to bacterial multiplication. Transfusion 1994; 34: 852-857.
31. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84: 1703-1721.
32. Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 1981; 9: 77-83.
33. Pamphilon DH, Blundell EL. Ultraviolet-B irradiation of platelet concentrates: a strategy to reduce transfusion recipient allosensitization. Seminars in Hematology 1992; 29: 113-121.
34. Sniecinski I, O'Donnell MR, Nowicki B et al. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402-1407.
35. Andreu G, Dewailly J, Leberre C et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988; 72: 964-969.
36. Saarinen UM, Kekomäki R, Siimes MA et al. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990; 75: 512-517.
37. van Marwijk Kooy M, van Prooijen HC, Moes M et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective randomized trial. Blood 1991; 77: 201-205.
38. Oksanen K, Kekomäki R, Ruutu T et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion 1991; 31: 588-594.
39. Williamson LM, Wimperis JZ, Williamson P et al. Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective randomized study. Blood 1994; 83: 3028-3035.
40. Novotny VMJ, van Doom R, Witvliet MD et al. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995; 85: 1736-1741.
41. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunisation and refractoriness: a randomized prospective study. Blood 1995; 85: 824-828.
42. Kurz M, Greinix H, Hocker P et al. Specificities of antiplatelet antibodies in multitransfused patients with haematooncological disorders. Br J Haemal 1996; 95: 564-569.
43. Heddle NM and Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995; 85: 603-606.
44. Oksanen K, Elonen E, for the Finnish Leukaemia Group: Impact of leucocyte-depleted blood components on the haematological recovery and prognosis of patients with acute myeloid leukaemia. Br J Haem 1993; 84: 639.
45. Bishop JF, McGrath K, Wolf MM et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71: 383-387.
46. Doughty HA, Murphy MF, Metcalfe P et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994; 66: 200-205.
47. Alcorta I, Pereira A, Ordinas A. Clinical and laboratory factors associated with platelet transfusion refractoriness: a case-control study. Brit J of Haem 1996; 93: 220-224.
48. Bock M, Muggenthaler K-H, Schmidt U et al. Influence of antibiotics on posttransfusion platelet increment. Transfusion 1996; 36: 952-954.
49. Norol F, Kuentz M, Cordonnier C et al. Influence of clinical status on the efficiency of stored platelet transfusion. Br J Haemal 1994; 86: 125-129.
50. Heal JM, Cowles J, Masel D et al. Antibodies to plasma proteins: an association with platelet transfusion refractoriness. Br J Haemal 1992; 80: 83-90.
51. Heal JM, Masel D, Blumberg N. Interaction of platelet Fc and complement receptors with circulating immune complexes involving the ABO system. Vox Sang 1996; 71: 205-211.
52. Tucker J, Murphy MF, Gregory WM el al. Apparent removal of graft-versus-leukaemia effect by lhe use of leucocyle-poor blood components in patients with acute myeloblastic leukaemia. Br J Haem 1989; 73: 572.
53. Copplestone A, Williamson P, Norfolk D et al. Wider benefits of leukodepletion of blood products. (Letter) Blood 1995; 86: 409-110.
54. McCann SR, Bacigalupo A, Gluckman E et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplantation 1994; 13: 233-237.
55. Killick SB, Win N, Marsh JCW et al. Pilot sludy of HLA alloimmunization after transfusion wilh pre-storage leucodepleted blood products in aplastic anaemia. Br J Haem 1997; 97: 677-684.
56. Muylle L, Wouters E, De Bock R et al. Reactions to platelet transfusion: the effect of the storage time of the concentrate. Transfusion Medicine 1992; 2: 289-293.
57. Heddle NM, Luba Klama RT, Singer J et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331: 625-628.
58. Stack G, Baril L, Napychank P et al. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units of red cells. Transfusion 1995; 35: 199-203.
59. Muylle L, Joos M, Wouters E et al. Increased tumor necrosis factor α(TNFα) interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNFα and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195-199.
60. Aye MT, Palmer DS, Giulivi A. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995; 35: 117-124.
61. Muylle L, Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14-17.
62. Dzieczkowski JS, Barrett BB, Nester D et al. Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995; 35: 20-25.
63. Mangano MM, Chambers LA, Kruskall MS. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. Am J Clin Pathol 1991; 95: 733-738.
64. Goodnough LT, Riddell J, Lazarus H et al. Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993; 65: 103-107.
65. Wadhwa M, Seghatchian J, Lubenko A et al. Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Br J Haem 1996; 93: 225-234.
66. Anderson NA, Gray S, Copplestone JA et al. A prospective randomised study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfusion Medicine 1997; 7: 33-39.
67. Muylle L, Wouters E, Peetermans ME. Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Transfusion 1996; 36: 886-890.
68. Williamson LM, Warwick RM. Transfusion-associated graft-versus-host disease and its prevention. Blood Reviews 1995; 9: 251-261.
69. BCSH Blood Transfusion Task Force (Chairman, D Voak) Working Party (Convener, LM Williamson). Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfusion Medicine 1996; 6: 261-271.
70. Akahoski M, Takanashi M, Masuda M et al. A case of transfusion associated graft versus host disease not prevented by white cell-reduction filters. Transfusion 1992; 32: 169-172.
71. Popovsky MA, Chaplin HC Jnr, Moore SB. Transfusion-related acute lung injury: a neglected serious complication of haemotherapy. Transfusion 1992; 32: 589-592.
72. Virchis AE, Patel RK, Contreras M et al. Acute non-cardiogenic lung oedema after platelet transfusion. BMJ 1997; 314: 880-882.
73. Lake CL. Normal Hemostasis. In: Lake CL, Moore RA, eds. Blood. Hemostasis, transfusion, and alternatives in the perioperative period. New York, Raven Press, 1995, p 3-17.
74. Sweeney JD, Holme S, Heaton A. Quality of platelet concentrates. Immunological Investigations 1995; 24: 353-370.
75. UKBTS/NIBSC Guidelines for the Blood Transfusion Service, 2nd edn. London, HMSO, 1993.
76. Murphy S, Rebulla P, Bertolini F et al. In vitro assessment of the quality of stored platelet concentrates. Trans Med Rev 1994 VIII: 29-36.
77. Bertolini F, Murphy S. Biomedical Excellence for Safter Transfusion (BEST) Working Party of the International Society of Blood Transfusion. A multicenter evaluation of reproducibility of swirling in platelet concentrates. Transfusion 1994; 34: 796-801.
78. Bertolini F, Murphy S. Biomedical Excellence for Safter Transfusion (BEST) Working Party of the International Society of Blood Transfusion. A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Transfusion 1996; 36: 128-132.
79. Wagner SJ, Robinette D. Evaluation of swirling, pH, and glucose tests for the detection of bacterial contamination in platelet concentrates. Transfusion 1996; 36: 989-993.
80. Bode AP. Platelet activation may explain the storage lesion in platelet concentrates. Blood Cells 1990; 16: 109-125.
81. Michelson AD, Adelman B, Barnard MR et al. Platelet storage results in a redistribution of glycoprotein Ib molecules: evidence for a large intraplatelet pool of glycoprotein Ib. J Clin Invest 1988; 81: 1734-1740.
82. Metcalfe P, Williamson LM, Reutelingsperger CPM et al. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometry study of different production methods. Br J Haem 1997; 98: 86-95.
83. Ribeiro A, Swann JC, Berndt MC. Alterations of the levels of glycoproteins Ib-IX and IIb-IIa in platelets stored at 22°C. Thrombosis Research 1992; 66: 619-627.
84. Rinder HM, Snyder EL, Bonan JL et al. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein Ilb/IIIa, and β-thromboglobulin release. Transfusion 1993; 33: 25-29.
85. George JN, Pickett EB, Heinz R. Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates. Transfusion 1988; 28: 123-126.
86. Krailadsiri P, Seghatchian J, Bode AP. Microvesicles in blood components: laboratory and clinical aspects. Clin Appl Thrombosis/Haemostasis 1997; 3: 86-95.
87. Fijnheer R, Pietersz RN, de-Korte D et al. Platelet activation during preparation of platelet concentrates: a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 1990; 30: 634-638.
88. Holme S, Sweeney JD, Sawyer S et al. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997; 37: 12-17.
89. Owens M, Holme S, Heaton A et al. Post-transfusion recovery of function of 5-day stored platelet concentrates. Br J Haem 1992; 80: 539-544.
90. Michelson AD, Barnard MR. MacGregor H et al. Evaluation of the in vivo function of transfused platelets or platelet substitutes in primates: novel three-color whole blood flow cytometric methods. Bethesda, Frozen Platelets and Platelet Substitutes in Transfusion Medicine, Uniformed Services University of the Heath Sciences, March 1996, p 46.
91. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvas Res 1973; 5: 169-179.
92. Escolar G, Mazzara R, Castillo R et al. The role of the Baumgartner technique in transfusion medicine: research and clinical applications. Transfusion 1994; 34: 542-549.
93. McGill M, Brindley DC. Effects of storage on platelet reactivity to arterial subendothelium during blood flow. J Lab Clin Med 1979; 94: 370-380.
94. Escolar G, Hagert-Whiting K, Bravo ML et al. Interaction of long-term stored platelets with vascular subendothelium. J Lab Clin Med 1987; 109: 147-154.
95. Mazzara R, Escolar G, Garrido M et al. Evaluation of the transfusion effectiveness of various platelet concentrates by means of an in vitro perfusion technique. Transfusion 1991; 31:308-312.
96. Kratzer MAA, Born GVR. Simulation of primary haemostasis in vitro. Haemostasis 1985; 15: 357-362.
97. Kristensen J, Eriksson L, Olsson K et al. Functional capacity of transfused platelets estimated by the Thrombostat 4000/2. Eur J Haematol 1993; 51: 152-155.
98. Eriksson L, Kristensen J, Olsson K et al. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Vox Sang 1996; 70: 69-75.
99. 51 Cr. Transfusion 1992; 32: 113-120.
100. Sloand EM, Yu M, Klein HG. Comparison of randomdonor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections. Transfusion 1996; 36: 955-959.
101. Bertolini F, Rebulla P, Marangoni F et al. Platelet concentrates stored in synthetic medium after filtration. Vox Sang 1992; 62: 82-86.
102. Joustra-Dijkhuis AM, Boomgaard MN, Pietersz RNI et al. Effect of filtration on subsequently stored platelet concentrates. Vox Sang 1994; 67: 22-27.
103. Weisbach V, Putzo A, Zingsem J et al. Leuckocyte depletion and storage of single-donor platelet concentrates. Vox Sang 1997; 72: 20-25.
104. Sweeney JD, Holme S, Stromberg RR et al. In vitro and in vivo effects of prestorage filtration of apheresis platelets. Transfusion 1995; 35: 125-130.